Company / Working Capital
Arbutus Biopharma Corp Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$88.5M
FY2025
5-year range
$88.5M / $149.4M
FY2021-FY2025
Trend
-20.8%
vs FY2024
Sector context
#197 of 213
Health Care
What the data says
Among 213 Health Care companies, Arbutus Biopharma Corp is in the bottom 8% for working capital. Working Capital has fluctuated over the past 10 years, ranging from $86M in FY2019 to $149M in FY2021.
Based on SEC 10-K filings.
$88M in FY2025 with a 5-year CAGR of -5.6%.
Declined from $110M to $88M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -9.2%
- 5-Year CAGR
- -5.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $88.5M Sector average $934.6M
▼
-90.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.6%, indicating a declining trend.
- In FY2025, working capital decreased 20.8% year-over-year.
- Ranks #197 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $88.5M | -20.8% |
| FY2024 | $111.7M | +2.0% |
| FY2023 | $109.5M | -7.4% |
| FY2022 | $118.3M | -20.8% |
| FY2021 | $149.4M | +26.5% |
| FY2020 | $118.2M | +37.4% |
| FY2019 | $86.0M | -27.1% |
| FY2018 | $118.0M | +2.8% |
| FY2017 | $114.7M | -5.9% |
| FY2016 | $122.0M | -29.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026